Merck KGaA Stock
€142.55
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | -0.660% | 0.702% | 2.208% | 31.290% | 17.334% | -12.845% | -23.056% |
| Bayer AG | -0.200% | 3.648% | -2.170% | 90.578% | 32.874% | -6.399% | 3.780% |
| Zoetis Inc. A | 0.250% | -3.224% | -2.025% | -48.775% | -39.605% | -62.357% | -61.769% |
| Biogen Inc. | -0.020% | 2.407% | 2.865% | 59.947% | 19.813% | -26.778% | -37.649% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
OmniAb Q2 Earnings Call Highlights
OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and
Merck KGaA Q2 Earnings Call Highlights
Key Points
- Interested in Merck KGaA? Here are five stocks we like better.
- Merck KGaA reported strong Q2 growth, with organic sales up 4.1% and EBITDA pre rising 9.3% organically to €1.6
Merck & Co., Inc. Q2 Earnings Call Highlights
Key Points
- Interested in Merck & Co., Inc.? Here are five stocks we like better.
- Q2 revenue rose 5% to $16.6 billion, driven by oncology, animal health and newer launches. Merck reported a